Medicine,
Journal Year:
2024,
Volume and Issue:
103(48), P. e40666 - e40666
Published: Nov. 29, 2024
Previous
research
has
indicated
a
possible
link
between
mobile
phone
usage
and
the
incidence
of
glaucoma.
This
study
employs
2-sample
Mendelian
randomization
(MR)
analysis
to
examine
causal
relationship
use
glaucoma
risk.
We
used
single
nucleotide
polymorphisms
(SNPs)
from
publicly
accessible
genome-wide
association
(GWAS)
datasets
as
instrumental
variables
(IVs).
The
primary
analytical
method
was
inverse
variance
weighted
(IVW)
approach,
with
MR-Egger
median
analyses
serving
complementary
methods.
Sensitivity
evaluated
using
Cochran’s
Q
test
regression.
results
demonstrate
effect
on
an
increased
risk
(OR
IVW
=
1.358,
95%
CI:
1.052–1.752,
P
.019;
OR
1.882,
0.53–6.682,
.337;
Weighted
1.387,
1.012–1.900,
.042;
MR-PRESSO
.026).
confirmed
robustness
reliability
these
findings.
identifies
potentially
modifiable
factor
for
glaucoma,
providing
new
avenues
exploring
specific
mechanisms
underlying
ocular
disorders.
Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(4), P. 850 - 850
Published: April 2, 2025
Glaucoma,
a
chronic
and
progressive
eye
disease,
is
significant
public
health
concern
responsible
for
substantial
proportion
of
global
vision
impairment
blindness
[...]
Vision,
Journal Year:
2025,
Volume and Issue:
9(2), P. 32 - 32
Published: April 11, 2025
Glaucoma
is
a
visual
disease
that
affects
millions
of
people,
and
early
diagnosis
can
prevent
total
blindness.
One
way
to
diagnose
the
through
fundus
image
examination,
which
analyzes
optic
disc
cup
structures.
However,
screening
programs
in
primary
care
are
costly
unfeasible.
Neural
network
models
have
been
used
segment
nerve
structures,
assisting
physicians
this
task
reducing
fatigue.
This
work
presents
methodology
enhance
morphological
biomarkers
images
obtained
by
smartphone
coupled
an
ophthalmoscope
deep
neural
network,
combines
two
backbones
dual
decoder
approach
improve
segmentation
these
as
well
new
combine
loss
weights
training
process.
The
were
numerically
evaluated
Dice
IoU
measures.
dice
values
experiments
reached
95.92%
85.30%
for
optical
92.22%
75.68%
cup,
respectively,
BrG
dataset.
These
findings
indicate
promising
architectures
task.
Journal of Medicinal Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 14, 2025
Based
on
two
major
risk
factors
of
glaucoma,
elevated
intraocular
pressure
(IOP)
and
senescence,
new
series
nitric
oxide
(NO)
donating
dasatinib
derivatives
1a-f,
2a-f
were
designed,
synthesized,
biologically
evaluated.
The
results
demonstrated
that
the
most
active
compound
2e
effectively
released
NO
increased
concentration
3',5'-cyclic
guanosine
monophosphate
in
human
trabecular
meshwork
cells,
as
well
maintained
senolytic
activity.
Topical
administration
chronic
ocular
hypertension
(COHT)
glaucoma
mice
not
only
significantly
eliminated
senescent
cells
retina
but
also
exhibited
potent
retinal
ganglion
(RGCs)
surviving,
IOP
lowering,
visual
function
protection
activities,
which
superior
to
those
dasatinib.
Compared
with
younger
adult
mice,
aged
COHT
resulted
more
severe
RGCs
loss,
while
a
greater
capacity
improve
survival.
Our
findings
show
dual
lowering
functions
could
be
promising
therapeutic
strategy
for
particularly
older
patients.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(1), P. 73 - 73
Published: Jan. 7, 2025
Background/Objectives:
Retinal
ganglion
cell
(RGC)
protection
represents
an
unmet
need
in
glaucoma.
This
study
assessed
the
neuroprotective,
antioxidant,
and
anti-inflammatory
effect
of
a
new
nutraceutical
formulation
named
Epicolin,
based
on
citicoline,
homotaurine,
epigallocatechin-3-gallate,
forskolin,
vitamins,
through
vitro
vivo
studies.
Methods:
The
neuroprotective
Epicolin
or
its
single
components,
compared
to
untreated
control
two
marketed
formulations
[Formulation
G
(FG)
N
(FN)],
was
evaluated
neuroblastoma
cells
(SH-SY5Y)
challenged
with
staurosporine.
antioxidant
potential
scavenging
activity
control,
FG
FN,
SH-SY5Y
oxygen
radical
absorbance
capacity
acellular
assay,
respectively.
Moreover,
protective
against
hypoxic
damage
Muller
(MIO-M1)
subjected
hypoxia.
efficacy
also
DBA/2J
glaucomatous
mice
use
pattern
electroretinogram
(PERG),
immunostaining,
real-time
PCR.
Results:
Among
tested,
only
showed
significant
attributable
synergistic
action
ingredients.
As
for
activity,
higher
FN.
Furthermore,
same
MIO-M1
reducing
HIF-1α
expression.
Finally,
treatment
protected
RGCs
from
loss
function,
as
demonstrated
by
PERG
analysis,
attenuated
their
death
enhancing
brain-derived
neurotrophic
factor
(BDNF)
interleukin-1
beta
(IL-1β)
tumor
necrosis
factor-alpha
(TNF-α)
Conclusions:
due
properties,
promising
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: Feb. 10, 2025
Using
follow-up
data
from
the
National
Health
and
Nutrition
Examination
Survey
(NHANES)
database,
we
have
collected
information
on
2572
subjects
used
generalized
linear
model
to
investigate
association
between
urinary
heavy
metal
levels
glaucoma
risk.
In
addition,
developed
an
individualized
risk
prediction
using
machine
learning
algorithms
further
interpreted
results
through
feature
importance
analysis,
local
cumulative
interaction
effects.
this
study,
found
significant
logarithmically
calculated
arsenic
(As)
metabolites,
especially
arsenochlorine
(AC),
after
adjusting
for
a
series
of
confounders,
including
creatinine
(β
=
1.090,
95%
CI:
0.313–1.835).
The
Shapley
Additive
Explanations
(SHAP)
analysis
clinical
scores
also
indicated
that
As
metabolites
promoted
more
severely
than
other
variables.
This
study
applied
first
time
explore
relationship
metals
while
analyzing
effects
multiple
exposures
disease,
improving
predictive
power
compared
conventional
models.
Our
provided
important
insights
into
potential
role
in
pathogenesis
glaucoma,
facilitated
discovery
new
biomarkers
early
diagnosis,
assessment,
timely
treatment
guided
public
health
measures
reduce
exposure.
European Journal of Pharmacology,
Journal Year:
2025,
Volume and Issue:
unknown, P. 177425 - 177425
Published: Feb. 1, 2025
This
study
is
a
systematical
review
regarding
the
glaucoma
treatment
with
drug-loaded
contact
lenses.
The
effectiveness
and
safety
about
that
were
summarized,
which
providing
effective
suggestions
guidance
for
clinical
research.
studies
published
up
to
May
1,
2024
on
of
sustained-release
lenses
searched
from
CNKI,
Wanfang
Data,
VIP,
PubMed,
Embase,
Cochrane
Library,
Medline.
CAMARADES
was
used
evaluate
literature
quality.
safety,
endpoints
intraocular
pressure
reduction
(IOPR)
duration
(IOP)
decline
during
analyzed
by
means
qualitative
quantitative
methods.
protocol
registration
number
CRD42024487157.
47
included.
In
trials,
patients
showed
50%
in
IOP
no
corneal
tissue
destruction
after
wearing
animal
experiments,
endpoint
IOPR
[MD=0.58,
95%CI
(0.37,
0.80),
P<0.00001]
medicated
group
significantly
better
than
eye
drops
group.
Subgroup
analysis
loaded
timolol
(TML),
TML
+
dorzolamide,
latanoprost,
compared
drops,
had
effect
reducing
IOP,
while
puerarin,
bimatoprost
statistical
difference.
Most
demonstrated
drugs
release
vitro
≥3
days
treatment.
exhibit
excellent
safety.
nanoparticle-loaded
containing
recommended
future
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(9), P. 1190 - 1190
Published: Sept. 10, 2024
Glaucoma
stands
as
a
primary
cause
of
irreversible
blindness
globally,
characterized
by
the
progressive
dysfunction
and
loss
retinal
ganglion
cells
(RGCs).
While
current
treatments
primarily
focus
on
controlling
intraocular
pressure
(IOP),
many
patients
continue
to
experience
vision
loss.
Therefore,
research
has
shifted
therapeutic
targets
aimed
at
preventing
or
delaying
RGC
death
optic
nerve
degeneration
slow
halt
disease
progression.
Traditional
ocular
drug
administration,
such
eye
drops
oral
medications,
face
significant
challenges
due
eye’s
unique
structural
physiological
barriers,
which
limit
effective
delivery.
Invasive
methods
like
intravitreal
injections
can
side
effects
bleeding,
inflammation,
infection,
making
non-invasive
delivery
with
high
bioavailability
very
desirable.
Nanotechnology
presents
promising
approach
addressing
these
limitations
in
glaucoma
treatment.
This
review
summarizes
approaches
involving
neuroprotective
drugs
combined
nanocarriers,
their
impact
for
future
use.
